Literature DB >> 24994581

Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease.

L Abenavoli1, C Luigiano, P H Guzzi, N Milic, C Morace, L Stelitano, P Consolo, S Miraglia, S Fagoonee, C Virgilio, F Luzza, A De Lorenzo, R Pellicano.   

Abstract

AIM: Non-alcoholic fatty liver disease (NAFLD) is a relevant public health matter in Western countries. The pathogenetic link between visceral fat, insulin resistance (IR) and NAFLD has been reported in literature. However, there are contradictions on the changes of adipokine levels in serum related to the presence of NAFLD. The aim of the present study was to evaluate the serum concentrations of a selected set of adipokines, that is, adiponectin, leptin, resistin and the pro-inflammatory cytokine interleukin-6 (IL-6) in overweight patients, and to clarify their relationship with NAFLD.
METHODS: Fasting serum levels of adipokines were determined in 42 consecutive overweight patients and in 25 lean controls. The degree of ultrasound (US) liver steatosis was graded according to the Hamaguchi score.
RESULTS: Liver steatosis was detected in 33 patients (78%) by US examination. Twelve patients with elevated transaminases levels showed significantly higher values of IR, leptin and resistin levels (P<0.05). Patients with steatosis presented a significantly higher leptin and a lower adiponectin levels (P<0.05) than controls. A significant inverse correlation was found between US steatosis progression and adiponectin and resistin levels (p<0.05). Considering the multiple logistic regression, adiponectin and leptin were good predictors to detect the presence of steatosis (p<0.05).
CONCLUSION: Our data support the concept that adipokine level changes are closely linked with IR. In addition, serum adiponectin and leptin levels may be used as diagnostic markers to determine the presence of NAFLD in overweight patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24994581

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  19 in total

Review 1.  From obesity through gut microbiota to cardiovascular diseases: a dangerous journey.

Authors:  Paolo Marzullo; Laura Di Renzo; Gabriella Pugliese; Martina De Siena; Luigi Barrea; Giovanna Muscogiuri; Annamaria Colao; Silvia Savastano
Journal:  Int J Obes Suppl       Date:  2020-07-20

Review 2.  Non-alcoholic fatty liver disease and psoriasis: So far, so near.

Authors:  Giulia Ganzetti; Anna Campanati; Annamaria Offidani
Journal:  World J Hepatol       Date:  2015-03-27

3.  Resistin Levels in Non-alcoholic Fatty Liver Disease Pathogenesis.

Authors:  Carmela Colica; Ludovico Abenavoli
Journal:  J Transl Int Med       Date:  2018-03-28

4.  S2FLNet: Hepatic steatosis detection network with body shape.

Authors:  Qiyue Wang; Wu Xue; Xiaoke Zhang; Fang Jin; James Hahn
Journal:  Comput Biol Med       Date:  2021-11-30       Impact factor: 6.698

5.  Hawthorn leaf flavonoids alleviate nonalcoholic fatty liver disease by enhancing the adiponectin/AMPK pathway.

Authors:  Zhongping Li; Jiaoya Xu; Peiyong Zheng; Lianjun Xing; Hongyi Shen; Lili Yang; Li Zhang; Guang Ji
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 6.  Metabolic aspects of adult patients with nonalcoholic fatty liver disease.

Authors:  Ludovico Abenavoli; Natasa Milic; Laura Di Renzo; Tomislav Preveden; Milica Medić-Stojanoska; Antonino De Lorenzo
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

7.  Exploiting the molecular basis of age and gender differences in outcomes of SARS-CoV-2 infections.

Authors:  Daniele Mercatelli; Elisabetta Pedace; Pierangelo Veltri; Federico M Giorgi; Pietro Hiram Guzzi
Journal:  Comput Struct Biotechnol J       Date:  2021-07-10       Impact factor: 7.271

8.  Therapeutic effect of hybrid training of voluntary and electrical muscle contractions in middle-aged obese women with nonalcoholic fatty liver disease: a pilot trial.

Authors:  Sechang Oh; Tsuyoshi Maruyama; Kiyoshi Eguchi; Takashi Shida; Emi Arai; Tomonori Isobe; Yoshikazu Okamoto; Junichi Shoda
Journal:  Ther Clin Risk Manag       Date:  2015-03-04       Impact factor: 2.423

9.  Non-alcoholic fatty liver disease severity, central fat mass and adinopectin: a close relationship.

Authors:  Ludovico Abenavoli; Laura DI Renzo; Pietro Hiram Guzzi; Rinaldo Pellicano; Natasa Milic; Antonino DE Lorenzo
Journal:  Clujul Med       Date:  2015-11-15

10.  Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Su Jong Yu; Won Kim; Donghee Kim; Jung-Hwan Yoon; Kyoungbun Lee; Jung Ho Kim; Eun Ju Cho; Jeong-Hoon Lee; Hwi Young Kim; Yoon Jun Kim; Chung Yong Kim
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.